Peptide evidence preview
Ipamorelin: evidence, mechanism, and limitations
A dose-free evidence preview of ipamorelin’s ghrelin-receptor mechanism, failed human clinical program, limitations, and source trail.
Direct answer
Direct answer
Ipamorelin is a synthetic peptide that activates the ghrelin receptor and stimulates endogenous growth-hormone release. Its selectivity is documented mainly in preclinical studies. The strongest controlled human trial, in postoperative ileus, did not show a significant benefit on its key or secondary efficacy outcomes, and marketed wellness claims remain unproven.
Public Evidence Passport preview
Preclinical mechanism + negative controlled human trial
The biological mechanism is supported mainly by laboratory and animal work. A controlled human program reached mid-stage testing but did not demonstrate a significant efficacy benefit for the studied indication.
- Strongest source tier
- Tier 4 — randomized controlled human trial
- Editorial review
- August 4, 2026
- Source coverage
- 4 inspectable records in this public preview
What matters
- The receptor mechanism is well characterized, but much of the selectivity evidence is preclinical.
- The completed controlled human trial was negative for the indication studied.
- Consumer claims around body composition, recovery, sleep, and healthy aging lack adequate controlled human support.
- Long-term human safety is not established, and ipamorelin is not approved for a clinical use in the United States or Canada.
Has ipamorelin been studied in humans?
Yes. A randomized trial studied recovery after bowel surgery. Its efficacy results did not show a significant advantage over placebo; it does not establish benefits for sleep, muscle gain, or general recovery.
| Source | Study design | Finding | Limit |
|---|---|---|---|
| Beck et al., 2014 | Multicenter, double-blind, placebo-controlled trial. 117 adults enrolled after bowel resection; 114 in the reported analysis populations. | No significant difference in the key or secondary efficacy analyses. | A small trial in surgical patients does not answer marketed wellness questions. |
| Raun et al., 1998 | Laboratory and animal pharmacology, including rat cells, rats, and swine. | Growth-hormone release and selectivity were characterized in these models. | These findings describe preclinical activity, not clinical benefit in people. |
Source notes updated . Added the human trial's study population, comparison, outcome, and limits, alongside the foundational preclinical paper.
Read a peptide study table
Read the study design, result, and limitations together, then follow the original source.
English narration and captions · 46 seconds
Watch this tutorial on YouTube
Read the transcript
A peptide claim is easier to judge when you can inspect the study behind it. Open a public evidence preview in Peptidia and find What the sources support. Read the study design first. Was it a human trial, an animal experiment, or a laboratory study? Note the population and the comparison group. Next, read the finding and its limit together. A biological effect does not establish a useful clinical benefit. A study in one patient group may not answer a different health question. Follow the source link to inspect the original record. Check what changed in the source notes and keep the review date in view. Peptidia is an educational reference. It does not prescribe treatments or provide doses.
Mechanism
Ipamorelin acts as an agonist of the growth hormone secretagogue receptor, also called the ghrelin receptor. Receptor activation stimulates the pituitary release of endogenous growth hormone. Foundational animal and laboratory studies reported more selective hormone release than earlier secretagogues.
That selectivity advantage should be described carefully: controlled human endocrine evidence is sparse, and a mechanistic description does not establish a useful clinical outcome.
What the human evidence found
Ipamorelin advanced to a multicenter, double-blind, placebo-controlled study in adults after bowel resection. The study did not find a statistically significant difference on its key efficacy endpoint or secondary efficacy analyses. Clinical development for that program was discontinued.
The contrast between positive rodent gastrointestinal findings and the negative human trial is an instructive example of why preclinical activity cannot be assumed to translate.
What remains uncertain
There are no adequate controlled human trials establishing the marketed wellness, body-composition, muscle, sleep, or recovery claims commonly associated with ipamorelin. Long-term safety is also insufficiently characterized.
Growth-hormone and related signaling raises safety questions involving glucose regulation, fluid retention, and proliferative pathways. Those questions require individualized clinical assessment and cannot be resolved by an educational profile.
Regulatory context
Ipamorelin is not approved by the U.S. Food and Drug Administration or Health Canada for a clinical indication. Availability through an unapproved or compounded channel is a separate question from evidence of benefit, product quality, and individual safety.
Inspect the record
Sources
- 01Ipamorelin, the first selective growth hormone secretagoguePubMed
Foundational preclinical characterization.
- 02Randomized proof-of-concept study of ipamorelin for postoperative ileusPubMed
Strongest controlled human evidence; efficacy analyses were negative.
- 03ClinicalTrials.gov
- 04Ipamorelin in a rodent model of postoperative ileusPubMed
Preclinical result that did not establish human benefit.
Go deeper
Carry the evidence library in your pocket.
Peptidia for iPhone adds the full reviewed library, inspectable study cards, grounded questions, and a private wellness journal—without numeric doses or protocols.